Apple debunks the hype around A.I. with a study showing that models struggle with complex reasoning, despite advanced ...

Apple researchers have uncovered a key weakness in today's most hyped AI systems – they falter at solving puzzles that ...

The Organisation for Economic Co-operation and Development (OECD) has established a set of principles for trustworthy AI that ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Based on its latest expense profile and business plan, after cutting its staff, Recursion said it now expects its projected cash runway to extend into the fourth quarter of 2027. Recursion will pay ...

Recursion Pharmaceuticals plans to slash one-fifth of its workforce as it looks to streamline its operations. The clinical-stage biopharmaceutical company said Tuesday it will reduce its workforce by ...

A team of MIT researchers developed a new algorithm that could eventually allow drones to constantly learn to adapt to ...

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at ...